2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Phase 1
1
Status
Withdrawn
1
Terminated
1
Completed
1
Sponsor Class
OTHER
3
Study Type
Interventional
3
Sponsor
Cancer Type
Thoracic
2
Other solid neoplasm
1
Conditions
Carcinoma, Non-Small-Cell Lung
2
Solid Tumour
1
Neoplasm Metastasis
1
Interventions
Cyclophosphamide
2067
Radiotherapy
1990
Cisplatin
1856
Carboplatin
1560
Gemcitabine
1454
Paclitaxel
1320
Bevacizumab
1320
pembrolizumab
1238
Docetaxel
1227
Oxaliplatin
1184
Capecitabine
1178
Fluorouracil
1083
Dexamethasone
979
Magnetic Resonance Spectroscopy
971
Nivolumab
936
Rituximab
929
Drug Therapy
915
Surveys and Questionnaires
899
Doxorubicin
845
Etoposide
843
Radiosurgery
816
Blood Specimen Collection
816
Irinotecan
784
Cytarabine
743
fludarabine
726
Leucovorin
684
Surgical Procedures, Operative
640
Lenalidomide
618
Biopsy
594
fludarabine phosphate
569
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
OTHER
×
L19-IL2 immunocytokine
×
Clear all
NCT03705403
2025-01-30
IMMUNOSABR2
Maastricht University Medical Center
Phase 2
Terminated
88 enrolled
NCT02086721
2017-05-31
L19-IL2
Maastricht Radiation Oncology
Phase 1
Completed
18 enrolled
NCT02735850
2017-05-23
ImmunoSABR
Maastricht Radiation Oncology
Phase 2
Withdrawn